Skip to main content

Peer Review reports

From: ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk “BCG failure” non muscle invasive bladder cancer: 3 years follow-up outcomes

Original Submission
3 Apr 2018 Submitted Original manuscript
26 Jun 2018 Author responded Author comments - Marco Racioppi
17 May 2018 Reviewed Reviewer Report - Dickon Hayne
Resubmission - Version 2
26 Jun 2018 Submitted Manuscript version 2
29 Oct 2018 Author responded Author comments - Marco Racioppi
11 Sep 2018 Reviewed Reviewer Report - Dickon Hayne
9 Oct 2018 Reviewed Reviewer Report - Reviewer 2
Resubmission - Version 3
29 Oct 2018 Submitted Manuscript version 3
15 Nov 2018 Author responded Author comments - Marco Racioppi
7 Nov 2018 Reviewed Reviewer Report - Reviewer 2
Resubmission - Version 4
15 Nov 2018 Submitted Manuscript version 4
18 Nov 2018 Author responded Author comments - Marco Racioppi
Resubmission - Version 5
18 Nov 2018 Submitted Manuscript version 5
21 Nov 2018 Author responded Author comments - Marco Racioppi
Resubmission - Version 6
21 Nov 2018 Submitted Manuscript version 6
Publishing
26 Nov 2018 Editorially accepted
6 Dec 2018 Article published 10.1186/s12885-018-5134-7

You can find further information about peer review here.

Back to article page